This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Latest comment: 9 years ago1 comment1 person in discussion
The insulin named in the article as "NovoLog Mix 70/30" is actually marketed, in the UK at least, as NovoMix 30. I suspect that this is a case of regional variation of brand names (e.g. paracetamol/acetaminophen). — Korax1214 (talk) 18:07, 24 April 2015 (UTC)Reply
Latest comment: 5 years ago1 comment1 person in discussion
Call me paranoid, but someone has added a statement that strikes me as something a staffmember at a massive lobbyist organization bankrolled by the US health insurance industry would add. It's basically an argument to stop prescribing modern (expensive) insulin. It reads "As of 2018 there is a lack of compelling evidence to conclude superiority of insulin aspart over human insulin in type 2 DM.[9] It is thus unclear why the shifting of people from human insulin to insulin aspart has occurred.[10] In type 1 DM it appears to result in slightly better blood sugar control.[11]". It is cited, but has only one source out of the millions of papers published annually, some also bankrolled by special interests. It screamed "agenda" immediately when I read it. It doesn't sit well with me. Habanero-tan (talk) 21:21, 31 July 2019 (UTC)Reply
